Hospital
ST. Vincent Infirmary Medical Center
ST. Vincent Infirmary Medical Center was paid $2.98M by Medicaid between Jan 2018 and Dec 2024, across 124 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 12% of everything it billed.
33Billing provider infoST. VINCENT INFIRMARY MEDICAL CENTER
SHERWOOD, AR 72120
SHERWOOD, AR 72120
33aNPI1629011002assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.98M
24GClaims215,244
24DCodes billed124
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#24 of 49
Median peer was paid$2.62M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,872 | $239K | |
| 2019 | 40,122 | $425K | |
| 2020 | 35,402 | $438K | |
| 2021 | 29,961 | $466K | |
| 2022 | 32,934 | $653K | |
| 2023 | 29,912 | $495K | |
| 2024incomplete | 19,041 | $260K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 2,820 | 2,430 | $342K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 11% | 3,661 | 3,019 | $340K |
| 70450 | Computed tomography, head or brain; without contrast material | 10.0% | 4,143 | 3,522 | $296K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 4.8% | 621 | 502 | $144K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.5% | 2,619 | 2,141 | $133K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 18,970 | 14,493 | $132K |
| 80053 | Comprehensive metabolic panel | 3.6% | 12,737 | 10,445 | $106K |
| 72125 | Computed tomography, cervical spine; without contrast material | 3.4% | 971 | 871 | $100K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 10,116 | 8,047 | $85K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.2% | 2,856 | 2,256 | $65K |
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 4,214 | 3,594 | $63K |
| 84484 | 2.0% | 6,915 | 5,188 | $59K |
112 more codes
| 83880 | 1.9% | 2,418 | $55K | |
| 81025 | 1.7% | 6,127 | $51K | |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 6,842 | $50K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 8,093 | $49K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 813 | $47K |
| 83690 | 1.4% | 5,195 | $43K | |
| 71045 | Radiologic examination, chest; single view | 1.4% | 5,483 | $40K |
| 80305 | 1.2% | 3,278 | $36K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 222 | $35K |
| 81001 | 1.2% | 7,174 | $34K | |
| 83735 | 1.1% | 4,730 | $34K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 774 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 775 | $32K |
| 99284 | Emergency room visit (serious) | 1.1% | 3,833 | $31K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 1,798 | $30K |
| 87430 | <1% | 2,638 | $29K | |
| 83605 | <1% | 2,473 | $25K | |
| 82550 | <1% | 2,215 | $22K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,600 | $22K |
| 70496 | <1% | 242 | $22K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,555 | $19K |
| 81003 | <1% | 5,458 | $19K | |
| 99285 | Emergency room visit (most serious) | <1% | 3,530 | $18K |
| 87081 | <1% | 1,931 | $16K | |
| 70498 | <1% | 146 | $15K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 975 | $14K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,283 | $13K |
| 85379 | <1% | 1,596 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,102 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,657 | $12K |
| 87077 | <1% | 876 | $11K | |
| 87040 | <1% | 1,448 | $11K | |
| 72131 | <1% | 95 | $11K | |
| 80076 | <1% | 835 | $10K | |
| 82962 | <1% | 2,623 | $10K | |
| 85610 | <1% | 3,967 | $9K | |
| 84145 | <1% | 635 | $9K | |
| 73564 | <1% | 318 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,563 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,231 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,388 | $8K |
| 80320 | <1% | 688 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 675 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 65 | $8K |
| 85027 | <1% | 1,285 | $7K | |
| 82565 | <1% | 569 | $7K | |
| 82553 | <1% | 1,007 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 145 | $7K |
| 85730 | <1% | 2,074 | $7K | |
| 86901 | <1% | 418 | $7K | |
| 73630 | <1% | 328 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,197 | $5K |
| 87210 | <1% | 931 | $5K | |
| 73610 | <1% | 229 | $5K | |
| 84703 | <1% | 434 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,438 | $4K |
| 73030 | <1% | 202 | $4K | |
| 73130 | <1% | 119 | $3K | |
| 80050 | General health panel | <1% | 53 | $2K |
| 87428 | <1% | 63 | $2K | |
| 80061 | Lipid panel | <1% | 425 | $2K |
| 72110 | <1% | 84 | $2K | |
| 86900 | <1% | 418 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 769 | $1K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $1K |
| 82803 | <1% | 80 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 717 | $1K |
| 84439 | <1% | 357 | $990.32 | |
| 84702 | <1% | 87 | $941.46 | |
| 90715 | <1% | 61 | $900.58 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 158 | $899.08 |
| 87186 | <1% | 176 | $886.89 | |
| 87420 | <1% | 73 | $874.63 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,702 | $729.52 |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $691.68 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $679.20 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 41 | $555.52 |
| 72100 | <1% | 33 | $553.65 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 896 | $535.59 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 255 | $473.30 |
| 82607 | <1% | 95 | $419.99 | |
| 84481 | <1% | 95 | $419.31 | |
| 72040 | <1% | 33 | $407.05 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,157 | $349.80 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 519 | $335.74 |
| 73110 | <1% | 17 | $326.93 | |
| 82746 | <1% | 68 | $266.82 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,643 | $235.36 |
| 73502 | <1% | 14 | $230.24 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 15 | $204.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 927 | $198.05 |
| A9270 | Non-covered item or service | <1% | 4,096 | $192.97 |
| 86850 | <1% | 76 | $189.05 | |
| 96376 | <1% | 58 | $168.55 | |
| 82009 | <1% | 35 | $139.64 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 53 | $138.70 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 430 | $129.63 |
| 82270 | <1% | 29 | $125.16 | |
| 80329 | <1% | 14 | $118.58 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,122 | $106.66 |
| 84132 | <1% | 16 | $73.82 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 140 | $52.66 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 131 | $38.08 |
| 81015 | <1% | 190 | $33.89 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 18 | $29.12 |
| 83721 | <1% | 59 | $27.24 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 12 | $7.60 |
| J2704 | Injection, propofol, 10 mg | <1% | 66 | $6.48 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 20 | $5.40 |
| 36416 | 0% | 28 | $0.00 | |
| 36600 | 0% | 62 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 133 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSZOSTEK, JOSHUA (VP OPERATIONAL FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Chi ST Vincent Hospital Hot Springs | Hot Springs, AR | $16.38M |
| ST Vincent Infirmary Medical Center | Little Rock, AR | $8.31M |
| Chi ST Vincent Hospital Hot Springs | Hot Springs, AR | $236K |
| ST. Vincent Infirmary Medical Center | Little Rock, AR | $121K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.